July 19, 2019 at 1:37 pm

Drug Risks Often Identified After FDA Approval

Sixty two percent of this specific drug class received the FDA’s most stringent warning, known as a “black box.” Most of the serious adverse effects were identified only after the drugs were on the market.
 “It raises the question of should we be regulating them differently,” said Joseph Ross, an associate professor of medicine at Yale School of Medicine, who has studied drug safety. Read the full article here.

 

July 17, 2019 at 10:18 am

Podcast Series Features MISSD Board Member’s Akathisia Story

Experts by experience is a term increasingly used to describe healthcare consumers and their families who share factual, first-hand experiences relating to pharmaceutical products and doctors’ care.  Gail Regenbogen, a MISSD board member, discusses her late husband, Howard’s, prescribed demise in our second  Akathisia Stories podcast.
Please listen and share so that others can be safer and better informed regarding critical adverse drug effects. Gail eloquently tells her family’s story with profound wisdom acquired after Howard’s akathisia-induced death. Listen here.

 

July 12, 2019 at 11:55 am

Akathisia Ads Taking Off in Chicago

MISSD is thrilled to reach 500 FB likes today. But even better is that our new Akathisia Awareness ads are taking off on many new Chicago train lines.  Way to roll!

July 9, 2019 at 3:50 am

MISSD Presents Akathisia Info at London Conference

Hundreds of doctors learned more about akathisia during MISSD’s recent presentation at the Royal College of Psychiatrists’ International Congress. Wendy Dolin shared case studies and MISSD videos that highlight the external and internal symptoms doctors should look for when assessing for akathisia.